EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaFebruary 23, 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, MyelomaFebruary 22, 2024
AMEN provides medical information for Arabic speakers in Israel and beyondAccess, MPEFebruary 13, 2024
EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaJanuary 30, 2024
MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapyMyelomaDecember 19, 2023
ASH 2023 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, MPE, MyelomaDecember 15, 2023
EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisationAccess, MPEDecember 15, 2023
Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, MyelomaDecember 9, 2023
